Revvity reported solid Q4 2025 results with revenue growth and improved earnings, highlighted by strong adjusted EPS performance and stable profitability despite margin pressure.

Revvity posted $699 million in revenue for Q3 2025 with slight organic growth and GAAP EPS of $0.40. Despite declines in operating and net income, the company reaffirmed full-year organic growth guidance and raised adjusted EPS outlook.

Revvity delivered $720 million in revenue and $53.9 million in net income during Q2 2025, outperforming expectations with disciplined execution and a robust innovation pipeline.

Revvity delivered strong Q1 2025 results, surpassing revenue and earnings forecasts, driven by resilience across its Life Sciences and Diagnostics businesses.

Revvity reported a solid fourth quarter and full year, driven by revenue growth and margin expansion. The company initiates full year 2025 guidance with revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00.

Revvity announced financial results for the third quarter ended September 29, 2024, with GAAP revenue of $684 million and GAAP EPS of $0.77. The company's adjusted EPS from continuing operations was $1.28. Revvity raised its full year 2024 adjusted EPS guidance and authorized a new $1 billion share repurchase program.

Revvity reported GAAP revenue of $692 million, a decrease from $709 million in the same period last year. GAAP EPS was $0.45, up from $0.28 year-over-year, while adjusted EPS was $1.22, slightly up from $1.21 in the previous year. The company is updating its full year revenue guidance to $2.77-$2.79 billion and raising its adjusted EPS guidance to a range of $4.70-$4.80.

Revvity announced its financial results for the first quarter of 2024, reporting a revenue of $650 million. The company's GAAP EPS was $0.21, and the adjusted EPS from continuing operations was $0.98. Revvity reaffirmed its full-year 2024 organic growth and adjusted EPS guidance.

Revvity reported a GAAP revenue of $696 million for the fourth quarter of 2023, compared to $741 million in the same period last year. GAAP EPS was $0.64, while adjusted EPS from continuing operations was $1.25. The company initiates full year 2024 guidance.

Revvity reported a challenging third quarter with a revenue of $671 million, a decrease compared to $712 million in the same period last year. The GAAP EPS was $0.08, while the adjusted EPS from continuing operations was $1.18. The company is focusing on factors they can control to navigate the increased market uncertainty.

Revvity's Q2 2023 results showed a decrease in revenue to $709 million compared to $896 million in the same period last year. GAAP EPS was reported at $0.28, down from $1.42 year-over-year, while adjusted EPS from continuing operations was $1.21, compared to $1.98 in the previous year. The company is updating its full-year 2023 guidance, expecting revenue between $2.80-$2.85 billion and adjusted EPS between $4.70-$4.90.

PerkinElmer reported a strong third quarter with a 21% increase in revenue to $1.17 billion and adjusted EPS of $2.31. The company also provided an optimistic outlook by raising full-year revenue and earnings guidance.

PerkinElmer announced financial results for the second quarter of 2021, with a revenue of $1.228 billion, a 51% increase in reported growth and a 41% increase in organic growth. GAAP EPS from continuing operations was $2.19, and adjusted EPS was $2.83. The company has initiated third quarter guidance and raised full-year revenue and earnings guidance. Additionally, they announced an agreement to acquire BioLegend.

PerkinElmer reported strong first-quarter results, with a 100% increase in reported revenue and a 92% increase in organic revenue. GAAP EPS from continuing operations was $3.37, and adjusted EPS was $3.72. The company initiated second-quarter guidance and raised full-year revenue and earnings guidance.

PerkinElmer reported a strong fourth quarter with a 68% increase in revenue to $1.355 billion and GAAP EPS of $3.38. The company's performance was driven by its response to the pandemic and focus on providing solutions. They also initiated guidance for Q1 and full year 2021.

PerkinElmer reported strong financial results for the third quarter of 2020, with significant revenue growth driven by the Diagnostics segment. The company's GAAP EPS and adjusted EPS also showed substantial increases compared to the same period last year, reflecting improved profitability.

PerkinElmer reported a strong second quarter with a 12% increase in revenue to $811.7 million and a GAAP EPS of $1.23. Adjusted EPS was $1.57. The Diagnostics segment saw substantial growth, offsetting a decline in the Discovery & Analytical Solutions segment.

PerkinElmer reported a slight increase in revenue to $652.4 million, a 1% increase compared to the first quarter of 2019. However, GAAP EPS decreased to $0.30 from $0.32, and adjusted EPS decreased to $0.67 from $0.69. The company withdrew its full-year 2020 financial guidance due to uncertainties related to the COVID-19 pandemic.

PerkinElmer announced its financial results for the fourth quarter and full year 2019, demonstrating strong performance. The company's Q4 revenue reached $805.5 million, reflecting a 6% reported growth and 5% organic growth. GAAP EPS from continuing operations was $0.58, while adjusted EPS reached $1.35. The company also provided FY20 GAAP EPS guidance range of $2.89 to $2.99 and adjusted EPS guidance of $4.50 to $4.60.